The majority of patients with metastatic ER+ breast cancer have or develop endocrine resistance, and thus both de novo and acquired resistance to endocrine therapy present significant hurdles to the effective treatment of breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.